References
  1. Gladdy RA, Qin LX, Moraco N, Agaram NP, Brennan MF, Singer S. Predictors of survival and recurrence in primary leiomyosarcoma. Annals of surgical oncology. 2013; 20:1851-7.
  2. Imura Y, Takenaka S, Outani H, Nakai T, Yasuda N, Nakai S, Wakamatsu T, Tamiya H, Okada S. Impact of Surgery and Chemotherapy on Metastatic Extrauterine Leiomyosarcoma. Curr Oncol. 2022; 29(4):2301-2311.
  3. Yang J, Du X, Chen K, Ylipää A, Lazar AJ, Trent J, Lev D, Pollock R, Hao X, Hunt K, Zhang W. Genetic aberrations in soft tissue leiomyosarcoma. Cancer Lett. 2009; 275(1):1-8.
  4. Kyriazoglou A, Liontos M, Ntanasis-Stathopoulos I, Gavriatopoulou M. The systemic treatment of uterine leiomyosarcomas: A systematic review. No news is good news? Medicine (Baltimore). 2021; 100(13):e25309.
  5. Shoushtari AN, Landa J, Kuk D, Sanchez A, Lala B, Schmidt N, Okoli C, Chi P, Dickson MA, Gounder MM, Keohan ML. Overall survival and response to systemic therapy in metastatic extrauterine leiomyosarcoma. Sarcoma. 2016; 2016.
  6. Barlin JN, Zhou QC, Leitao MM, Bisogna M, Olvera N, Shih KK, Jacobsen A, Schultz N, Tap WD, Hensley ML, Schwartz GK. Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome. Neoplasia. 2015; 17(2):183-9.
  7. Guo X, Jo VY, Mills AM, Zhu SX, Lee CH, Espinosa I, Nucci MR, Varma S, Forgó E, Hastie T, Anderson S. Clinically relevant molecular subtypes in leiomyosarcoma. Clinical cancer research. 2015; 21(15):3501-11.
  8. Oosten AW, Seynaeve C, Schmitz PI, Den Bakker MA, Verweij J, Sleijfer S. Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin. Sarcoma. 2009; 2009.
  9. Lamm W, Natter C, Schur S, Köstler WJ, Reinthaller A, Krainer M, Grimm C, Horvath R, Amann G, Funovics P, Brodowicz T, Polterauer S. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma. BMC Cancer. 2014; 14:981.
  10. Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017; 18(10):1397-1410.
  11. Tirumani SH, Deaver P, Shinagare AB, Tirumani H, Hornick JL, George S, Ramaiya NH. Metastatic pattern of uterine leiomyosarcoma: retrospective analysis of the predictors and outcome in 113 patients. J Gynecol Oncol. 2014; 25(4):306-12.
  12. Farid M, Ong WS, Tan MH, Foo LS, Lim YK, Chia WK, Soh LT, Poon D, Lee MJ, Ho ZC, Jeevan R, Chin F, Teo M, Quek R. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease. Am J Clin Oncol. 2013; 36(4):368-74.
  13. Bartosch C, Afonso M, Pires-Luís AS, Galaghar A, Guimarães M, Antunes L, Lopes JM. Distant Metastases in Uterine Leiomyosarcomas: The Wide Variety of Body Sites and Time Intervals to Metastatic Relapse. Int J Gynecol Pathol. 2017; 36(1):31-41.
  14. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature reviews Clinical oncology. 2011; 8(3):151-60.
  15. Coffelt SB, de Visser KE. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol. 2015; 36(4):198-216.
  16. Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y, Kroemer G. STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. Cancer Res. 2015; 75(18):3812-22.
  17. Salvagno C, Ciampricotti M, Tuit S, Hau CS, van Weverwijk A, Coffelt SB, Kersten K, Vrijland K, Kos K, Ulas T, Song JY. Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nature cell biology. 2019; 21(4):511-21.